Neue Studien: Europe PMChttps://www.psoriasis-news.de/articles.html/1_articles/page/5/?d=1Neue Studien: Europe PMCdeDiagnostic Algorithm for Axial Involvement in Psoriatic Arthritis.https://www.psoriasis-news.de/articles.html/1_articles/diagnostic-algorithm-for-axial-involvement-in-psoriatic-arthritis-r553/Weiterlesen

]]>553Fri, 03 Apr 2026 18:19:13 +0000Enzymatically-modified isoquercitrin alleviates skin inflammation, mast cell degranulation, and vascular hyperpermeability in a mouse model of plaque psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/enzymatically-modified-isoquercitrin-alleviates-skin-inflammation-mast-cell-degranulation-and-vascular-hyperpermeability-in-a-mouse-model-of-plaque-psoriasis-r552/Weiterlesen

]]>552Fri, 03 Apr 2026 18:19:13 +0000Effectiveness, Quality of Life and Durability of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Real-World Evidence from the PRIMMA Study.https://www.psoriasis-news.de/articles.html/1_articles/effectiveness-quality-of-life-and-durability-of-risankizumab-in-patients-with-moderate-to-severe-psoriasis-real-world-evidence-from-the-primma-study-r551/IntroductionPatients with moderate-to-severe psoriasis often experience significant physical symptoms and notable psychosocial distress. Pruritus is the most bothersome symptom and a key contributor to sleep disturbances and reduced quality of life (QoL). Though biologics such as risankizumab have advanced clinical management, real-world evidence of patient-reported outcomes (PROMs) and objective pruritus assessment remains limited. This study assessed risankizumab's effectiveness in improving QoL, symptom burden, and sleep and evaluated the feasibility of nocturnal scratch monitoring using a wearable sensor.

Methods

PRIMMA was a multicenter, prospective, non-interventional study conducted in Israel among adults with moderate-to-severe psoriasis initiating label-approved risankizumab therapy. Outcomes were assessed at baseline and week 52, and included Dermatology Life Quality Index (DLQI), static Psoriasis Global Assessment (sPGA), Pruritus Numeric Rating Scale (PNRS), Psoriasis Symptoms Scale (PSS), Medical Outcomes Study Sleep Scale (MOS-SS), Work Productivity and Activity Impairment (WPAI), and adverse events. Objective nocturnal scratch activity was measured using ADAM digital patch sensors in a subgroup of patients.

Results

In 136 participants, the median age was 51 years, 57% were male, 43% were female, and 35% were bio-naïve. At week 52, 58% achieved DLQI 0/1 (versus 5.1% at baseline; p < 0.001) and 81% had PNRS 0-3 (versus 21% at baseline; p < 0.001). sPGA 0/1 was reached by 77% at week 52, and components of PSS and WPAI improved significantly. In patients who achieved any favorable outcome (DLQI 0/1, PNRS 0-3, sPGA 0/1) at week 24, ≥ 68% maintained it at week 52, demonstrating treatment durability. In the digital subcohort (n = 14), sensor data confirmed significant reduction in nocturnal scratch duration at week 4 and week 16 compared to baseline (both p ≤ 0.032). Adverse events were mostly mild to moderate.

Conclusions

In real-world practice, risankizumab showed substantial improvements in QoL, pruritus, sleep, and work/activity impairment in moderate-to-severe psoriasis. Digital scratch monitoring showed reduction in nocturnal scratch duration. Integrating objective digital measures with PROMs may enable more data-driven, individualized management in psoriasis care.

Clinical trial registration

ClinicalTrials.gov Identifier NCT04780516.

Weiterlesen

]]>551Fri, 03 Apr 2026 18:19:13 +0000'I Didn't Know, I Definitely Guessed.' Exploring Pre-Registration Podiatry Students' Approach to Identifying Dermatological Conditions in Different Skin Tones, a Mixed Methods Study.https://www.psoriasis-news.de/articles.html/1_articles/i-didnt-know-i-definitely-guessed-exploring-pre-registration-podiatry-students-approach-to-identifying-dermatological-conditions-in-different-skin-tones-a-mixed-methods-study-r550/Weiterlesen

]]>550Fri, 03 Apr 2026 18:19:13 +0000Impact Profiles in Psoriatic Arthritis: An Exploratory Latent Class Analysis of the Assessment of SpondyloArthritis International Society Health Index.https://www.psoriasis-news.de/articles.html/1_articles/impact-profiles-in-psoriatic-arthritis-an-exploratory-latent-class-analysis-of-the-assessment-of-spondyloarthritis-international-society-health-index-r549/ObjectiveWe aimed to identify and characterize distinct subgroups of patients with psoriatic arthritis (PsA) based on their responses to the Assessment of SpondyloArthritis international Society Health Index (ASAS HI), using latent class analysis (LCA).

Methods

We performed an exploratory LCA on 17 dichotomous ASAS HI items in a cohort of patients with PsA (n = 90). Model adequacy was evaluated by log-likelihood, Akaike information criterion (AIC), Bayesian information criterion (BIC), entropy, and average posterior probabilities (AvePP). Clinical measures (Psoriatic Arthritis Impact of Disease [PsAID], Disease Activity Index for Psoriatic Arthritis [DAPSA], tender/swollen joint counts, treatment) were compared across classes. Sensitivity analyses with 3 to 4 classes assessed robustness.

Results

A 6-class solution was retained, ordered from class 0 (lowest impact) to class 5 (highest impact). Mean ASAS HI ranged from 1.2 in class 0 to 11.6 in class 5, with parallel increases in PsAID and DAPSA. Conditional probabilities revealed distinct profiles: class 0 had minimal impairment, classes 1-2 showed predominantly physical function limitations of mild to moderate severity, class 3 combined physical and emotional function burden, class 4 was characterized by dominant participation and social impact, and class 5 displayed severe multidimensional impairment. All classes had AvePP > 0.86. Sensitivity analyses with K = 3 and K = 4 reproduced the same gradient of impact but provided less granular separation.

Conclusion

LCA of the ASAS HI identified 6 clinically meaningful health impact profiles in PsA. These findings support the use of the ASAS HI as a multidimensional tool capable of capturing diverse patient experiences and may help inform individualized management strategies in PsA.

Weiterlesen

]]>549Fri, 03 Apr 2026 10:26:50 +0000Comparative Efficacy of Methotrexate Versus Cyclosporine in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis: A Systematic Review and Meta-Analysis.https://www.psoriasis-news.de/articles.html/1_articles/comparative-efficacy-of-methotrexate-versus-cyclosporine-in-the-treatment-of-moderate-to-severe-chronic-plaque-psoriasis-a-systematic-review-and-meta-analysis-r548/P = .27; I2 = 80%) and PASI 90 (RR = 1.03; 95% CI: 0.50-2.11; P = .94; I2 = 65%) between methotrexate and cyclosporine. Reduction at 4, 8, and 12 weeks (mean difference = -1.15 [95% CI: -0.23 to 2.53]; P = .10) showed no difference between the 2 treatments, but the difference was not statistically significant. In terms of safety, methotrexate had fewer adverse events overall but was more associated with elevated liver enzymes (RR = 13.35). Methotrexate and cyclosporine show comparable efficacy in moderate-to-severe psoriasis, though methotrexate has a more favorable safety profile.

Weiterlesen

]]>548Fri, 03 Apr 2026 10:26:50 +0000Effectiveness and safety of acupoint catgut embedding for patients with mild psoriasis and overweight: study protocol of a multicenter double-blind randomized controlled trialhttps://www.psoriasis-news.de/articles.html/1_articles/effectiveness-and-safety-of-acupoint-catgut-embedding-for-patients-with-mild-psoriasis-and-overweight-study-protocol-of-a-multicenter-double-blind-randomized-controlled-trial-r547/No abstract supplied.

Weiterlesen

]]>547Fri, 03 Apr 2026 10:26:50 +0000Multi‑omics and their integration in psoriasis research (Review).https://www.psoriasis-news.de/articles.html/1_articles/multi%E2%80%91omics-and-their-integration-in-psoriasis-research-review-r546/Weiterlesen

]]>546Fri, 03 Apr 2026 10:26:50 +0000IL-17, IL-23, and IL-36α Expression in Palmoplantar Psoriasis, Palmoplantar Eczema, and Plaque Psoriasis: Implications on Diagnosis and Treatment Selection.https://www.psoriasis-news.de/articles.html/1_articles/il-17-il-23-and-il-36%CE%B1-expression-in-palmoplantar-psoriasis-palmoplantar-eczema-and-plaque-psoriasis-implications-on-diagnosis-and-treatment-selection-r545/BackgroundPalmoplantar psoriasis exhibits greater treatment resistance compared to other psoriatic plaques and presents clinical and histopathological overlap with palmoplantar eczema. This study aimed to investigate treatment resistance mechanisms in palmoplantar psoriasis and assess the contribution of IL-17, IL-23, and IL-36α to the differential diagnosis of palmoplantar psoriasis and eczema. Immunohistochemical levels of these cytokines were measured in paired acral and non-acral psoriatic samples.

Methods

We retrospectively included 73 patients: 25 with only palmoplantar psoriasis, 25 with palmoplantar eczema, and 23 with both conditions and concurrent plaque psoriasis. Clinical and histopathological diagnoses were confirmed. Immunohistochemical analyses were conducted using preparations stained for IL-17, IL-23, and IL-36α.

Results

In psoriasis cases, immunohistochemical examination of biopsies from both body and palmoplantar regions showed lower IL-17 and IL-36α expression in acral regions compared to non-acral regions. In palmoplantar eczema patients, IL-17 and IL-23 expression was higher than in palmoplantar psoriasis patients; however, IL-36α expression was similar in both conditions.

Conclusions

The diminished expression of IL-17 and IL-36α in palmoplantar psoriasis compared to other body sites may contribute to variable responses to targeted treatments. These findings suggest the potential for developing distinct biological treatments for these regions.

Weiterlesen

]]>545Fri, 03 Apr 2026 10:26:50 +0000Circulating metabolites associated with psoriasis in the UK Biobank and the HUNT Study: A cross-sectional study of 470,352 participants.https://www.psoriasis-news.de/articles.html/1_articles/circulating-metabolites-associated-with-psoriasis-in-the-uk-biobank-and-the-hunt-study-a-cross-sectional-study-of-470352-participants-r544/BackgroundPsoriasis is recognized as a systemic inflammatory disease associated with metabolic dysregulation. Understanding these metabolic changes may reveal biomarkers to elucidate disease mechanisms and predict comorbidities. While previous studies have identified psoriasis-associated metabolites, findings are often limited by sample sizes and lack validation.

Objectives

To identify circulating metabolites associated with psoriasis, including disease severity and psoriatic arthritis. Further, we investigated whether the metabolic signature was disease-specific compared to other immune-mediated inflammatory diseases (IMIDs).

Methods

We performed a cross-sectional analysis of 470,352 White/European individuals from the UK Biobank (n=453,428) and HUNT (n=16,924). Nuclear Magnetic Resonance spectroscopy was used to quantify metabolite levels, covering lipoprotein fractions and subfractions, fatty acids, and small-molecular metabolites. For each metabolite, we performed multivariable linear regression adjusting for age, sex, BMI, smoking status, and use of lipid-lowering medications.

Results

The metabolomic profile of psoriasis was largely consistent across the two populations. In the model adjusted for age and sex, 123 metabolic measures were associated with psoriasis. After full adjustment, only Glycoprotein acetyls (GlycA) remained associated with psoriasis (coefficient [95% CI]: 0.09 [0.07-0.11] in UK Biobank and 0.11 [0.06-0.17] in HUNT). In HUNT, severe psoriasis exhibited more pronounced metabolic alterations compared to non-severe psoriasis. Across both populations, phenylalanine levels were highly elevated in psoriatic arthritis compared to cutaneous psoriasis (0.44 [0.29-0.60] in UK Biobank and 0.47 [0.28-0.67] in HUNT). In comparisons across IMIDs, atopic dermatitis and cutaneous-limited psoriasis exhibited milder metabolic alterations, and psoriasis in HUNT showed a distinct lipoprotein profile.

Conclusions

This large-scale study confirms metabolic alterations in individuals with psoriasis and highlights phenylalanine as a potential biomarker for joint involvement in psoriasis. The distinct metabolomic profile of psoriasis relative to other IMIDs suggests a potentially unique systemic profile. These findings offer a foundation for advancing biomarker research and mechanistic studies for psoriasis.

Weiterlesen

]]>544Fri, 03 Apr 2026 10:26:50 +0000Environmental and Neighborhood Determinants of Psoriasis: A Systematic Review of Pollution, Built Environment, and Socioeconomic Vulnerability on Psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/environmental-and-neighborhood-determinants-of-psoriasis-a-systematic-review-of-pollution-built-environment-and-socioeconomic-vulnerability-on-psoriasis-r543/Weiterlesen

]]>543Fri, 03 Apr 2026 10:26:50 +0000Association between Epicardial Adipose Tissue Thickness and Clinical and Metabolic Parameters in Patients with Psoriasis and Psoriatic Arthritis: A Cross-Sectional Study from Türkiye.https://www.psoriasis-news.de/articles.html/1_articles/association-between-epicardial-adipose-tissue-thickness-and-clinical-and-metabolic-parameters-in-patients-with-psoriasis-and-psoriatic-arthritis-a-cross-sectional-study-from-t%C3%BCrkiye-r542/BackgroundPsoriasis and psoriatic arthritis (PsA) are chronic inflammatory diseases that affect not only the skin and joints but also the cardiovascular system.

Aim

To investigate the relationship between epicardial adipose tissue (EAT) thickness and anthropometric measurements, laboratory parameters, and clinical variables in patients with psoriasis and PsA.

Methods

This cross-sectional study included 65 patients with psoriasis vulgaris (with or without PsA) and 54 healthy controls. Demographic, clinical, and laboratory data of the participants were recorded. EAT, left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), interventricular septum thickness (IVS), and ejection fraction (EF) were measured by echocardiography. Associations between EAT thickness and patient parameters were evaluated using Spearman correlation and multivariate linear regression analyses.

Results

The mean ages of the patient and control groups were 43.88 ± 13.1 years and 44.81 ± 12.88 years, respectively. Low-density lipoprotein cholesterol, LVESD, and IVS were significantly higher in the control group compared with psoriasis patients (P = 0.021, P < 0.001, P < 0.001, respectively). C-reactive protein (CRP) levels (P < 0.001), systolic blood pressure (P < 0.001), diastolic blood pressure (P = 0.023), and EAT thickness (P < 0.001) were significantly higher in the patient group. Disease duration (P = 0.028) and PASI (P = 0.012) were significantly greater in psoriasis patients with PsA. EAT positively correlated with body mass index (BMI) (r = 0.307, P = 0.024), CRP (r = 0.344, P < 0.001), and systolic blood pressure (r = 0.185, P = 0.044).

Conclusions

EAT thickness was higher in patients with psoriasis than in control participants. EAT positively correlated with BMI, CRP, and systolic blood pressure.

Weiterlesen

]]>542Fri, 03 Apr 2026 10:26:50 +0000Peroxisome Proliferator-Activated Receptors (PPARs) in Psoriasis: Metabolic Intersections, Molecular Mechanisms, and Potential Treatmentshttps://www.psoriasis-news.de/articles.html/1_articles/peroxisome-proliferator-activated-receptors-ppars-in-psoriasis-metabolic-intersections-molecular-mechanisms-and-potential-treatments-r541/No abstract supplied.

Weiterlesen

]]>541Fri, 03 Apr 2026 10:26:50 +0000Psoriasis Flare Following Interleukin-17 (IL-17) Inhibition and Recent Streptococcal Infection: A Case Report Highlighting Management Complexityhttps://www.psoriasis-news.de/articles.html/1_articles/psoriasis-flare-following-interleukin-17-il-17-inhibition-and-recent-streptococcal-infection-a-case-report-highlighting-management-complexity-r540/No abstract supplied.

Weiterlesen

]]>540Fri, 03 Apr 2026 10:26:50 +0000Psoriasis under B-cell depleting therapies in multiple sclerosis: a retrospective multicenter analysis.https://www.psoriasis-news.de/articles.html/1_articles/psoriasis-under-b-cell-depleting-therapies-in-multiple-sclerosis-a-retrospective-multicenter-analysis-r537/BackgroundB-cell depleting therapies (BCDT), including ocrelizumab, ofatumumab, and ublituximab, are highly effective disease-modifying therapies for multiple sclerosis (MS). Several case reports have raised concerns about new-onset or exacerbation of psoriasis under BCDT.

Objectives

This article aims to analyze clinical characteristics, treatment courses, and outcomes of MS patients who developed or experienced worsening of psoriasis during BCDT.

Design

This retrospective, multicenter analysis included patients from four German university hospitals (Düsseldorf, Hannover, Bochum, Giessen).

Methods

We retrospectively screened 3228 MS patients under BCDT between 2020 and 2024 for development of psoriasis or an exacerbation of a known psoriasis. Clinical data, including Expanded Disability Status Scale, Psoriasis Area and Severity Index scores, treatment regimens, and comorbidities, were analyzed.

Results

Among 3228 patients treated with BCDT, 7 developed new-onset psoriasis and 10 showed exacerbation of preexisting psoriasis. The median time to psoriasis onset or worsening was 13 months (3-83 months) under continuous treatment with BCDT. Topical therapies were effective in most cases, but a change of MS treatment or initiation of psoriasis-specific immunotherapies, including the interleukin-17A-antibody secukinumab, was required in four patients.

Conclusion

Psoriasis onset or worsening during BCDT is rare. While most cases are manageable with standard psoriasis treatments, severe cases may necessitate therapy adjustments. The potential immunological interplay between MS and psoriasis treatment warrants further investigation.

Weiterlesen

]]>537Mon, 30 Mar 2026 08:02:12 +0000Disentangling Nicotine vs Non-Nicotine Components of Tobacco Exposure in Psoriasis and Psoriatic Arthritis: A Multivariable and Trans-Ethnic Mendelian Randomization Study.https://www.psoriasis-news.de/articles.html/1_articles/disentangling-nicotine-vs-non-nicotine-components-of-tobacco-exposure-in-psoriasis-and-psoriatic-arthritis-a-multivariable-and-trans-ethnic-mendelian-randomization-study-r536/ObjectiveTo disentangle tobacco constituents in psoriasis, we contrasted nicotine exposure-proxied by the nicotine metabolite ratio (NMR)-with smoking intensity (cigarettes per day, CPD) and evaluated cross-ancestry effects.

Methods

This study applied multivariable Mendelian randomization (MR) jointly modeling genetically proxied NMR (instrumented using variants from a European-ancestry GWAS) and CPD to estimate their independent effects on liability to psoriasis and psoriatic arthritis (PsA). Chronic obstructive pulmonary disease (COPD) served as a positive control. Cross-ancestry generalizability was tested using a trans-ethnic MR (TEMR) framework under conditional likelihood with Nelder-Mead optimization. Sensitivity analyses assessed pleiotropy, heterogeneity, directionality (Steiger), MRLap, RadialMR, and multiple testing (Benjamini-Hochberg).

Results

NMR showed an independent association with higher PsA risk irrespective of CPD (OR = 1.104, 95% CI: 1.039-1.174). CPD retained an independent effect on overall psoriasis after conditioning on NMR (OR = 1.305, 95% CI: 1.082-1.573), while the NMR effect on psoriasis attenuated (P > 0.05). In univariable MR, genetically predicted NMR increased psoriasis risk in Europeans (EUR; OR = 1.032, 95% CI: 1.013-1.051). CPD associated with psoriasis in EUR (OR = 1.130, 95% CI: 1.031-1.239) and strongly in Hispanics (HIS; OR = 1.448, 95% CI: 1.434-1.463), with suggestive evidence in East Asians. Reverse-direction MR indicated psoriasis liability correlated with lower CPD across EUR, EAS, AFR, and HIS (β < 0, Padj < 0.05).

Conclusion

This study supports ancestry-specific differences and suggests distinct roles of nicotine-related versus non-nicotine tobacco smoke constituents in psoriasis and its subtypes, while the underlying biological mechanisms remain to be clarified.

Weiterlesen

]]>536Mon, 30 Mar 2026 08:02:12 +0000A Study on Lifestyle and Dietary Factors in Psoriasis: Global Prevalence Trends in Working-Age Populations, Association with LE4 Lifestyle Factors, and Mendelian Randomization Analysis of Dietary Causal Effects.https://www.psoriasis-news.de/articles.html/1_articles/a-study-on-lifestyle-and-dietary-factors-in-psoriasis-global-prevalence-trends-in-working-age-populations-association-with-le4-lifestyle-factors-and-mendelian-randomization-analysis-of-dietary-causal-effects-r535/BackgroundPsoriasis is a chronic immune-mediated skin disease influenced by genetic, environmental, and lifestyle factors, with increasing burden among working-age adults.

Objective

To examine global trends in psoriasis prevalence among working-age adults, evaluate associations with lifestyle factors using a simplified Life's Essential 4 (LE4) index, and explore potential dietary causal relationships through Mendelian randomization (MR).

Methods

Global prevalence trends from 1990 to 2021 were analyzed using GBD 2021 data, calculating age-standardized rates (ASR) and estimated annual percentage changes (EAPC), with projections to 2031. Regional variations across SDI levels were also assessed. The LE4 index, derived from core lifestyle components of the Life's Essential 8 framework using NHANES data, was evaluated via survey-weighted logistic regression and restricted cubic spline analysis. Two-sample MR analyses were conducted using the inverse-variance weighted (IVW) method to assess dietary traits.

Results

The global prevalence of psoriasis among working-age adults increased from 555.7 to 600.6 per 100,000 (EAPC: 0.22%), with projections reaching 631.6 by 2031; Notably, upward trends were consistently observed across all SDI regions. Higher LE4 scores (≥81.2) were associated with lower odds of psoriasis (OR: 0.518, P=0.040). MR analyses suggested that genetically predicted fizzy drink consumption increased risk (OR: 1.57, P=0.0215), whereas salad vegetable intake showed a protective association (OR: 0.85, P=0.0224).

Conclusion

The burden of psoriasis among working-age adults shows a modest global increase with regional heterogeneity. Healthier lifestyle patterns and favorable dietary factors were associated with reduced risk, highlighting the importance of modifiable behaviors in prevention strategies.

Weiterlesen

]]>535Mon, 30 Mar 2026 08:02:12 +0000Sensitive skin in patients with inflammatory chronic cutaneous disorders: results from an observational study on psoriasis, atopic dermatitis and hand eczema.https://www.psoriasis-news.de/articles.html/1_articles/sensitive-skin-in-patients-with-inflammatory-chronic-cutaneous-disorders-results-from-an-observational-study-on-psoriasis-atopic-dermatitis-and-hand-eczema-r534/BackgroundData on the prevalence of sensitive skin in patients with chronic inflammatory skin diseases are lacking. The aim of this study was to address this gap.

Methods

This observational study included patients with psoriasis, atopic dermatitis or chronic hand eczema who attended the Unit of Dermatology of Ferrara and Messina, Italy, between June and December 2023. All participants completed a 10-item questionnaire for the diagnosis of sensitive skin (score range: 0-10). Participants were classified as having sensitive skin if they scored ≥4.

Results

A total of 188 subjects were included, of whom 82 had psoriasis (mean Psoriasis Area and Severity Index [PASI] 4.2±5.1), 59 had atopic dermatitis (Eczema Area and Severity Index [EASI] 3.5±6.7) and 47 had hand eczema (Hand Eczema Severity Index [HECSI] 39.3±3.26). The mean questionnaire scores were 2.6±2.4 for psoriasis, 4.7±2.9 for atopic dermatitis, and 3.0±2.1 for hand eczema, with significant differences observed between atopic dermatitis and both psoriasis (P<0.001) and hand eczema (P<0.001). The prevalence of sensitive skin was higher among atopic dermatitis patients compared to those with psoriasis (P<0.001) and hand eczema (P<0.01).

Conclusions

In the present study, which should be regarded as a pilot due to the relatively small number of cases included, sensitive skin was both more prevalent and more severe in patients with atopic dermatitis compared to those with psoriasis and hand eczema. Atopic dermatitis appears to promote skin sensitivity, independently of its clinical severity.

Weiterlesen

]]>534Mon, 30 Mar 2026 08:02:12 +0000IL-17A Inhibitors Therapy Affect Oral Fungal and Bacterial Microbiome in Psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/il-17a-inhibitors-therapy-affect-oral-fungal-and-bacterial-microbiome-in-psoriasis-r533/Weiterlesen

]]>533Mon, 30 Mar 2026 08:02:12 +0000Spatial transcriptomic profiling reveals body site-specific inflammatory differences in psoriasis lesionshttps://www.psoriasis-news.de/articles.html/1_articles/spatial-transcriptomic-profiling-reveals-body-site-specific-inflammatory-differences-in-psoriasis-lesions-r532/No abstract supplied.

Weiterlesen

]]>532Mon, 30 Mar 2026 08:02:12 +0000Machine learning meets psoriasis: identifying key lactylation biomarkers as potential targets for diagnosis and therapieshttps://www.psoriasis-news.de/articles.html/1_articles/machine-learning-meets-psoriasis-identifying-key-lactylation-biomarkers-as-potential-targets-for-diagnosis-and-therapies-r531/No abstract supplied.

Weiterlesen

]]>531Mon, 30 Mar 2026 08:02:12 +0000Long-term safety and efficacy in paediatric psoriasis: Remaining challenges.https://www.psoriasis-news.de/articles.html/1_articles/long-term-safety-and-efficacy-in-paediatric-psoriasis-remaining-challenges-r530/No abstract supplied.

Weiterlesen

]]>530Mon, 30 Mar 2026 08:02:12 +0000Paediatric psoriasis and biologics: An evidence gap in plain sight.https://www.psoriasis-news.de/articles.html/1_articles/paediatric-psoriasis-and-biologics-an-evidence-gap-in-plain-sight-r529/No abstract supplied.

Weiterlesen

]]>529Mon, 30 Mar 2026 08:02:12 +0000Development of transdermal nanofilm containing fluticasone propionate: In-vitro, in-vivo correlation.https://www.psoriasis-news.de/articles.html/1_articles/development-of-transdermal-nanofilm-containing-fluticasone-propionate-in-vitro-in-vivo-correlation-r528/BackgroundPsoriasis is one of the chronic inflammatory skin conditions, affecting about 2-3% of the world population. Steroidal treatment are only best choice of treatments, but it is often associated with side effects due to higher lipophilicity.

Objectives

In this work, a nanoparticle-loaded transdermal film was developed to maintain nanoparticle integrity in the skin.

Methods

Fluticasone propionate loaded chitosan nanoparticles (NPs) were developed, and their particle size, zeta potential, drug loading, entrapment efficiency and scanning electron microscope (SEM) images were determined. The NPs-loaded film was further characterized for appearance, thickness and Fourier Transform Infrared (FTIR) spectra, and an in vitro and in vivo permeation study was conducted.

Results

The particle size of FSNPs was found to be 250nm with +32.4 ±1.5 mV zeta potential, great entrapment efficiency and spherical in shape. In vivo dermato-kinetic studies showed long-term, confined drug release from the NP-formulated film in the epidermal layers, compared with the film containing free drug.

Conclusion

The study demonstrated that the FSNPs-loaded film showed higher skin permeation, which is effective for managing psoriasis and warrants further evaluation.

Weiterlesen

]]>528Mon, 30 Mar 2026 08:02:12 +0000Hibiscetin-Loaded Nanogel Ameliorated the Severity of IMQ-Induced Psoriasis-Like Inflammation in Mice via Down-Regulating Interleukins/TNF-α/NF-κB.https://www.psoriasis-news.de/articles.html/1_articles/hibiscetin-loaded-nanogel-ameliorated-the-severity-of-imq-induced-psoriasis-like-inflammation-in-mice-via-down-regulating-interleukinstnf-%CE%B1nf-%CE%BAb-r527/IntroductionThe rising incidence of inflammatory skin diseases, including psoriasis, has necessitated new treatment approaches. This paper focuses on the development of a hibiscetin-impregnated nanogel that reduces the severity of skin inflammation.

Methods

Imiquimod (IMQ) was used to induce psoriasis-like inflammation in animal models, and the nanogel's worthiness was compared. Nanogel was prepared in different concentrations of hibiscetin, namely F1 (1) and F2 (2), and characterized in terms of appearance, size, charge, spreadability, pH, release kinetics of the drug, skin penetration and stability.

Results

Lab analyses showed that the nanogel possessed desirable characteristics, with an average particle size of 205 nm, a polydispersity index (PDI) of 0.385, and a surface charge of -69.5 mV. Its morphology was confirmed to be spherical by scanning electron microscopy (SEM). The nanogel demonstrated powerful anti-inflammatory properties, including the disappearance of redness and skin thickening, reduced pro-inflammatory cytokine concentrations, reduced oxidative stress markers, and apoptosis-mediated cell death in vivo. Hibiscetin, as an effect of IMQ, also had a reparative effect on damaged skin as evidenced by histopathological studies.

Conclusion

The results imply that hibiscetin-conjugated nanogels offer an option for improving the delivery and therapeutic efficacy of inherent compounds in the management of skin inflammation.

Weiterlesen

]]>527Thu, 12 Mar 2026 13:34:20 +0000